Đang chuẩn bị liên kết để tải về tài liệu:
Chapter 085. Neoplasms of the Lung (Part 13)

Table 85-5 Randomized Studies of Adjuvant Chemotherapy in NSCLC Stu dy Treatment mber Nu of Year 5edian M zard Ha Value p Patients Survival Survival Ratio (%) (95% CI) EC OG Surgery 242 9% 246 3 39 months vs. 0.9 3 (0.74– .56 0 3590 →RT vs. Surgery + post-op concurrent (II–IIIA) 38 1.18) 3 RT + cis/etoposide 3% months AL Surgery 603 1% 606 5 R N 6 0.9 (0.8– .59 0 PI (I–IIIA) alone vs. Surgery + post-op mitomycin/vindesin e/cisplatin 3% 4 1.1) Big Surgery 189 33 months 1.0 2 (0.77– .90 1.35) 0 Lung Trial alone vs. Surgery + 192 (I–IIIB) post-op 34 chemotherapy a months IAL Surgery 405 0% 361 4 R N 0.8 6 (0.76– 0.03 0.98) . | Chapter 085. Neoplasms of the Lung Part 13 Table 85-5 Randomized Studies of Adjuvant Chemotherapy in NSCLC Stu dy Treatment Nu mber of Patients 5- Year Survival M edian Survival Ha zard Ratio 95 CI P Value EC OG 3590 II-IIIA Surgery RT vs. Surgery post-op concurrent RT cis etoposide 242 246 3 9 3 3 39 months vs. 38 months 0.9 3 0.74- 1.18 0 .56 AL PI I-IIIA Surgery alone vs. Surgery post-op 603 606 5 1 N R 0.9 6 0.8- 0 .59 mitomycin vinde sin e cisplatin 4 3 1.1 Big Lung Trial I-IIIB Surgery alone vs. Surgery post-op chemotherapy 189 192 33 months 34 months 1.0 2 0.77- 1.35 0 .90 IAL TIB-IIIA Surgery alone vs. Surgery post-op Cis VP16 vinca 405 361 4 0 4 4.5 N R 0.8 6 0.76- 0.98 0.03 UF TIA-IB Surgery alone vs. Surgery post-op UFT 488 469 8 5 8 8 0.7 1 0.52- 0.98 0 .04 CA LGB IB Surgery alone vs. Surgery 172 5 78 0.8 0 0.60- 0 ASCO 06 post-op carbo paclitaxel 172 7 9 5 months 95 months 1.07 .10 NC Surgery 241 5 73 0.6 0 I-CIB-II alone vs. Surgery post-op Cis vinorelbine 241 4 9 6 months 94 months 9 0.52- 0.91 .04 AN Surgery 433 4 44 0.7 0 ITA IB II IIIA alone vs. Surgery post-op Cis vinorelbine 407 3 1 5 months 66 months 9 50- 88.5 .017 Chemotherapy allowed mitomycin cisplatin ifosfamide mitomycin vinblastine cisplatin cisplatin vindesine cisplatin vinorelbine. Note RT radiation therapy NR not reported UFT tegafur and uracil. The role of adjuvant chemotherapy for stage IB disease is undefined. Subset analysis of all the randomized studies showed no benefit in patients .